NASDAQ:CTMX - CytomX Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $10.64 -0.25 (-2.30 %) (As of 05/23/2019 04:00 PM ET)Previous Close$10.89Today's Range$10.44 - $10.793452-Week Range$8.94 - $27.20Volume285,774 shsAverage Volume492,744 shsMarket Capitalization$482.11 millionP/E RatioN/ADividend YieldN/ABeta0.57 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., and Pfizer Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. Receive CTMX News and Ratings via Email Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTMX Previous Symbol CUSIPN/A CIK1501989 Webhttp://www.cytomx.com/ Phone650-515-3185Debt Debt-to-Equity Ratio0.22 Current Ratio4.21 Quick Ratio4.21Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$59.50 million Price / Sales8.10 Cash FlowN/A Price / Cash FlowN/A Book Value$2.71 per share Price / Book3.93Profitability EPS (Most Recent Fiscal Year)($2.03) Net Income$-84,600,000.00 Net Margins-111.27% Return on Equity-73.62% Return on Assets-18.90%Miscellaneous Employees137 Outstanding Shares45,311,000Market Cap$482.11 million Next Earnings Date8/14/2019 (Estimated) OptionableOptionable CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions What is CytomX Therapeutics' stock symbol? CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX." How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics Inc (NASDAQ:CTMX) issued its earnings results on Thursday, May, 9th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.22. The biotechnology company had revenue of $29.49 million for the quarter, compared to the consensus estimate of $13.59 million. CytomX Therapeutics had a negative return on equity of 73.62% and a negative net margin of 111.27%. View CytomX Therapeutics' Earnings History. When is CytomX Therapeutics' next earnings date? CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for CytomX Therapeutics. What price target have analysts set for CTMX? 8 brokerages have issued 1-year price objectives for CytomX Therapeutics' shares. Their predictions range from $13.24 to $34.00. On average, they anticipate CytomX Therapeutics' stock price to reach $21.28 in the next year. This suggests a possible upside of 100.0% from the stock's current price. View Analyst Price Targets for CytomX Therapeutics. What is the consensus analysts' recommendation for CytomX Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytomX Therapeutics. What are Wall Street analysts saying about CytomX Therapeutics stock? Here are some recent quotes from research analysts about CytomX Therapeutics stock: 1. Cantor Fitzgerald analysts commented, ": We are initiating coverage of Overweight rating and 12-month price target of $21/share. CytomX stock currently trades at an EV of ~$100M ($8.80/sh cash), and the shares are down about 27% YTD (vs. +8.5% for NBI), triggered by updates at its R&D day earlier this year. We believe that the company’s lead early-stage clinical assets, based on modified antibodies, are partially de-risked and are highly discounted at the current valuation. For CX-2009, we think that evolving clinical updates in the next 6-12 months should alleviate investor concerns about its safety profile and that risk of potential clinical setback is overstated." (5/13/2019) 2. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (4/30/2019) 3. HC Wainwright analysts commented, "We utilize a probability of approval of 70% for we employ a 10% discount rate, and a 29% effective tax rate, yielding a total value of $1.6B, or a price per share of $34, assuming 47.6M shares outstanding and roughly $329M in cash and equivalents as of end-4Q19." (4/3/2019) Has CytomX Therapeutics been receiving favorable news coverage? News articles about CTMX stock have been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. CytomX Therapeutics earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. Who are some of CytomX Therapeutics' key competitors? Some companies that are related to CytomX Therapeutics include AnaptysBio (ANAB), Xencor (XNCR), Tricida (TCDA), Enanta Pharmaceuticals (ENTA), Pacira Biosciences (PCRX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Zogenix (ZGNX), Zai Lab (ZLAB), Prestige Consumer Healthcare (PBH), Nabriva Therapeutics (NBRV), Madrigal Pharmaceuticals (MDGL), Innoviva (INVA), Endo International (ENDP) and Heron Therapeutics (HRTX). What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Amicus Therapeutics (FOLD), Progenics Pharmaceuticals (PGNX), Portola Pharmaceuticals (PTLA), TherapeuticsMD (TXMD), Alibaba Group (BABA), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX). Who are CytomX Therapeutics' key executives? CytomX Therapeutics' management team includes the folowing people: Dr. Sean A. McCarthy, Chairman, CEO & Pres (Age 52)Mr. Debanjan Ray, Sr. VP & CFO (Age 41)Dr. Rachel Wallach Humphrey, Sr. VP & Chief Medical Officer (Age 58)Dr. Hoyoung Huh, Special Advisor to Chief Exec. Officer (Age 50)Dr. W. Michael Kavanaugh, Sr. VP, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 63) Who are CytomX Therapeutics' major shareholders? CytomX Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.53%), Wellington Management Group LLP (7.28%), Perceptive Advisors LLC (7.00%), Perceptive Advisors LLC (7.00%), FMR LLC (4.72%) and Victory Capital Management Inc. (3.65%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Lloyd A Rowland, Rachel Humphrey, Robert I Tepper, Sean A Mccarthy and William Michael Kavanaugh. View Institutional Ownership Trends for CytomX Therapeutics. Which major investors are selling CytomX Therapeutics stock? CTMX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, FIL Ltd, Goldman Sachs Group Inc., Citigroup Inc., Man Group plc, Hamilton Lane Advisors LLC, Wells Fargo & Company MN and Renaissance Technologies LLC. Company insiders that have sold CytomX Therapeutics company stock in the last year include Debanjan Ray and Sean A Mccarthy. View Insider Buying and Selling for CytomX Therapeutics. Which major investors are buying CytomX Therapeutics stock? CTMX stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Victory Capital Management Inc., Wellington Management Group LLP, First Manhattan Co., Perceptive Advisors LLC, Perceptive Advisors LLC, Spark Investment Management LLC and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for CytomX Therapeutics. How do I buy shares of CytomX Therapeutics? Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is CytomX Therapeutics' stock price today? One share of CTMX stock can currently be purchased for approximately $10.64. How big of a company is CytomX Therapeutics? CytomX Therapeutics has a market capitalization of $482.11 million and generates $59.50 million in revenue each year. The biotechnology company earns $-84,600,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. CytomX Therapeutics employs 137 workers across the globe. What is CytomX Therapeutics' official website? The official website for CytomX Therapeutics is http://www.cytomx.com/. How can I contact CytomX Therapeutics? CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected] MarketBeat Community Rating for CytomX Therapeutics (NASDAQ CTMX)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 256 (Vote Outperform)Underperform Votes: 198 (Vote Underperform)Total Votes: 454MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: Strangles Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.